Article
A new tacrine-melatonin hybrid reduces amyloid burden and behavioral deficits in a mouse model of Alzheimer's disease.
Neurotoxicity research - 1 May 2010
Spuch Carlos, Antequera Desiree, Isabel Fernandez-Bachiller M, Isabel Rodríguez-Franco M, Carro Eva
Abstract excerpt
Alzheimer's disease (AD) is a progressive degenerative disorder characterized by the presence of amyloid deposits, neurofibrillary tangles and neuron loss. Emerging evidence indicates that antioxidants could be useful either for the prevention or treatment of AD. Tacrine and melatonin are well-known drugs which act as an acetylcholinesterase inhibitor and a free radical scavenger, respectively. In this study, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
